The FDA has approved Kite’s Yescarta (axicabtagene ciloleucel) drug for a new indication — initial treatment for patients with relapsed or refractory large B-cell lymphoma (LBCL), which its parents company Gilead said is the first chimeric antigen receptor (CAR) T-cell therapy to have done so.
Source: Drug Industry Daily